Abstract:Hepatitis C virus (HCV) is a small (approximately 55 to 65 nm), spherical, enveloped, hepatotropic RNA virus that causes acute and chronic hepatitis in humans. Persistent virus infection with HCV often leads to cirrhosis and hepatocellular carcinoma (HCC). At present there is neither a selective antiviral therapy nor a preventive vaccine. The only available treatment option is a long-acting pegylated-interferon-alpha, given in combination with nucleoside analog ribavirin, which is not very effective. Molecular studies of HCV began with the successful cloning of its genome in 1989. For many years, research to develop therapeutics was stalled by the inability to grow virus in tissue culture. A major milestone was achieved with the recent development of a robust cell culture system for HCV propagation. HCV proteins assemble and form replication complexes on modified host membranes, called as membranous webs. Even though HCV is detected and targeted by host immune mechanisms, it establishes and maintains a life-long persistent infection. HCV has evolved multiple strategies to survive and persist in hostile cellular environments; and the viral population is known to rapidly change during the course of a natural infection thereby escaping immune surveillance. Rapid mutations also help virus to survive by selecting for the variants which are resistant to antiviral drugs. Although precise mechanisms regulating HCV entry into hepatic cells via receptors remain unknown, HCV also has the capability of direct cell-to-cell transmission. The extremely complex and incompletely understood nature of the HCV lifecycle has complicated the discovery of new therapies. A complete understanding of the functional roles played by the HCV proteins during HCV lifecycle is vital for developing a successful cure. This review deals with current status of efforts in addressing these daunting tasks and challenges in developing therapeutics against chronic and rapidly changing hepatitis C virus.

Novel therapeutic options for chronic hepatitis C

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Novel therapeutic strategies for chronic hepatitis B

New advances in drug therapy of chronic hepatitis B infection

Development of novel therapeutics for chronic hepatitis B

HBV life cycle and novel drug targets

Novel delivery methods for treatment of viral hepatitis: an update

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Novel hepatitis C drugs in current trials

Novel Approaches Towards Conquering Hepatitis B Virus Infection

Hepatitis C virus: molecular biology & current therapeutic options

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Current trends and advances in antiviral therapy for chronic hepatitis B

Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

Recent progress in direct-acting antiviral agents for chronic hepatitis C

Optimal management and outlook for antiviral therapy of chronic HBV infection

Recent Advance in Antiviral Drugs for Hepatitis C.

New development of small molecule compounds for hepatitis C therapy

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C